Julie Fradette
Chercheuse universitaire
Axe Médecine régénératrice
Médecine régénérative
Biologie cellulaire
Prolifération, différenciation et mort cellulaires
Interactions cellulaires
Biologie vasculaire et endothéliale
Sciences des os, de la peau et du cartilage
Autres sciences de la santé
Génie médical et biomédical
Biotechnologies médicales
Dermatologie
Dernières nouvelles
Voir toutPublications
Voir tout-
article Rioux Y, Fradette J, Hayward CJ, Séguin V, Maciel Y, Bégin-Drolet A, Ruel J
Innovative Sutureless Fabrication Strategy for Tissue-Engineered Pediatric Heart Valves Using an Evolutive Support System
Ann Biomed Eng 2026.
-
article Ricard-Blum S, Fradette J
An update on the landscape of collagen bioactive fragments
FEBS J 293 (13), 2026.
-
article Zhao J, Yu B, Fradette J, Annabi B, Petropavlovskaia M, Eliopoulos N
Preconditioning with StemRegenin 1 enhances human adipose stromal/stem cells proliferation, migration, and protection against antimycin A
Mol Ther Methods Clin Dev 33 (4), 2025.
Projets
- Engineering bioactive dressings from mesenchymal cells to enhance healing of irradiated skin wounds, du 2022-04-01 au 2027-03-31
- Skin Investigation Network of Canada (SkIN Canada), du 2020-01-01 au 2027-02-14
- GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease, du 2024-04-01 au 2028-03-31
- Epidermolysis bullosa multidisciplinary team focusing on developing an effective cure for this severe rare skin disease, du 2025-03-01 au 2026-12-31
- Clinical trial for dystrophic epidermolysis bullosa (EB) using GMEB-SASS, a genetically modified EB skin substitute, du 2025-04-01 au 2028-03-31
- Toward a combined gene therapy and tissue engineering novel treatment for junctional epidermolysis bullosa, du 2025-04-01 au 2028-03-31
- Urethral reconstruction using tissue engineering, final steps towards clinical translation, du 2025-04-01 au 2030-03-31
- Roles of matricryptins (bioactive extracellular matrix fragments) in adipose tissue, du 2020-04-01 au 2026-03-31
- Développement de greffons d’épiderme autologue en combinant thérapie génique et génie tissulaire pour traiter l’épidermolyse bulleuse jonctionnelle, du 2024-04-01 au 2025-03-31
- Urethral reconstruction using tissue engineering, final steps towards clinical translation, du 2024-10-01 au 2025-03-31